STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7
Clinical trials for STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a PARP inhibitor boost chemo for tough lung cancer?
Disease control CompletedThis study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Lung cancer drug shows promise in keeping tumors at bay after chemo
Disease control CompletedThis phase III trial investigates whether sunitinib, a drug that blocks tumor blood vessel growth, can help patients with advanced non-small cell lung cancer maintain their response after initial chemotherapy. Participants who did not worsen after four cycles of platinum-based ch…
Matched conditions: STAGE IV NON-SMALL CELL LUNG CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC